Interest of PET-PSMA Imaging Potentiated by Androgen Blockade in Patients with Biological Relapse or Persistent Biological Disease of a Localized Prostatic Adenocarcinoma After Initial Treatment
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Degarelix (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- Acronyms PREFAcE
- 18 Feb 2025 Status changed from recruiting to completed.
- 14 Mar 2022 Planned End Date changed from 4 Feb 2022 to 14 Mar 2024.
- 14 Mar 2022 Planned primary completion date changed from 19 Sep 2021 to 29 Mar 2023.